Blood metabolic fingerprinting of rats, subjected to subchronic lead exposure

Aleksei I. Chemezov¹, Marina P. Sutunkova¹, Ilzira A. Minigalieva¹, Svetlana V. Klinova¹, Iulia V. Ryabova¹

INTRODUCTION
Environmental pollution with heavy metals is vital issue in the present time. Lead, as one of the environmental contaminators, deserves attention due to its applicability in human activity and its xenobiotic character.

METHODS
In this study we used an untargeted metabolomic approach – the metabolomic fingerprinting method. Lead acetate was intraperitoneally injected to rats within the framework of a subchronical experiment and blood samples were analyzed by UHPLC-MS. Metabolite expression was qualitatively compared between treated and control groups. For substances with a significant content difference, tandem CID spectra for structure elucidation were obtained using an exact mass search by generating a list of potential formulas, by a characteristic fragments database search, using in silico mass spectra prediction, and by looking for a specific fragmentation rearrangement.

RESULTS
Untargeted metabolomic analysis shows 37 metabolites with significant changes in expression in comparing the control and exposure group. Annotation by the fragment spectra analysis was carried out for 8 metabolites. These include epoxy-derivative of linoleic acid, hydroxy- and oxoacylcarnitines of long-chain fatty acids, 15-hydroxyeicosatetraenoic acid, acylcarnitine of middle-chain fatty acid and lysophosphatidylserine derivative.

CONCLUSIONS
Literature analysis allows to establish known functions of annotated metabolites. Connections to manifestations of lead poisoning were established. Specifically, hydroxy- and oxoacylcarnitines are intermediates in the beta-oxidation process of fatty acids – increased concentration of these derivatives may be a sign of disturbances in this process under the influence of lead-induced oxidative stress. Epoxy- and hydroxyderivatives of polyunsaturated fatty acids, which demonstrate elevated concentration levels possess regulatory activity (vasodynamic, antiapoptotic, and antioxidative action) on the one hand, and presumably are biomarkers of oxidative stress. Elevated levels of lysophosphatidylserine may be evidence of apoptotic process intensification.
partially. Negative effects of lead exposure are known. These include anemia, porphyria, glucosuria, hypophosphatemia, and aminoaciduria. Neurological disorders after chronic lead exposure include children's growth delay, intelligence reduction, memory degradation, hearing loss, and brain damage. There are existing metabolomic investigations on lead action in humans. Changes in metabolism of amino acids, urea and porphyrines were observed in a urine metabolomic study for people who live near a lead-battery recycling plant. Also, it was established, through a blood metabolomic experiment, that lead-associated chronic diseases imply changes in metabolism of amino acids, xenobiotics, lipids, energetical exchange metabolites, and peptides. The aim of the present work is to ascertain blood metabolites that change expression under lead exposure in a subchronical experiment with intraperitoneal injection, and to review these functions in the context of lead intoxication.

In the study were discovered changes in the expression of such compounds as long- and middle-chain acylcarnitines, phosphatidylserine, hydroxy- and epoxy-PUFA derivatives – these facts may provide evidence about disturbances in the lipid oxidation process, inflammation and intensification of apoptotic processes.

**METHODS**

The study flowchart is given in Figure 1.

**Reagents**

The reagents used included: lead acetate, distilled water, saline, methanol HPLC grade, water HPLC grade, acetonitrile HPLC grade, and formic acid HPLC grade.

**Animal experiment design**

An experiment was conducted using own breeding colony white rats, aged 4–5 months and body weight from 210 to 290 g. Two groups – 'Lead' and 'Control' – were formed, both with 11 individuals. All animals received a standard feeding ration PK-120, whose composition and characteristics are given in Table 1. Three times per week both groups had intraperitoneal injections; the 'Lead' group received a lead acetate solution in distilled water with lead content in count to single dose
11 mg/kg body weight; the ‘Control’ group received 2 mL saline solution. Total lead dose received by one animal corresponded to LD50 for lead acetate – it was established empirically that such dosing manner is effective for intoxication signs manifestation\textsuperscript{14}. The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Local Ethics Committee of the Yekaterinburg Medical Research Center for Prophylaxis and Health Protection in Industrial Workers (Protocol No 8 dated 18.11.2018).

**Blood sampling**

Blood was taken in vacuum tubes after the lapse of 6 weeks, with a preliminary injection of heparin, and stored until analysis at -50°C.

**Blood functional indices**

Quantification of hemoglobin levels was conducted by the hematological analyzer ‘Methic 18’ used according to the diagnostic kits. Reticulocyte was counted using optical microscopy after brilliant cresyl blue staining. Other measured parameters were determined using appropriate methods and kits\textsuperscript{15}.

**Blood pressure measurements**

Instrument complex ‘CODA-HT8’ with software from Kent scientific corporation was used for registration of heart rate, systolic and diastolic blood pressure.

**HPLC-MS sample pretreatment**

Four blood samples were randomly selected from both groups of animals. Sample preparation was conducted according to Cheng et al.\textsuperscript{16}. In brief, 100 mcL of serum, separated at 4000 r/min for 10 min, was mixed with 400 mcL of ice-cold methanol for fibrine precipitation at 12000 r/min. Serum was held at 4°C during one hour and finally centrifugated at 14000 r/min. Supernatant was separated for analysis.

**HPLC-MS analysis**

HPLC-MS analysis was conducted using a tandem quadrupole time-of-flight mass spectrometer Agilent 6545 AdvanceBio Q-TOF, connected with HPLC Agilent 1290 Infinity II.

**Liquid chromatography**

Samples were preliminary separated using a Zorbax Eclipse Plus C18 RRHD 1.8 μm 2.1×50 mm column. Gradient elution was made as described at Cheng et al.\textsuperscript{16}. Eluent composition was: phase A – 0.1% formic acid solution in water; and phase B – 0.1% formic acid solution in acetonitrile. Column temperature was 40°C, gradient parameters were: 0 min – B 8%, 2 min – B 20%, 8 min – B 45%, 20 min – B 85%, 24 min – B 95%, 26 min – B 8%, and 28 min – B 8%.

**Mass-spectrometry data acquisition and processing**

Sample analysis was conducted using the vendor’s software Agilent MassHunter Data Acquisition. Agilent Qualitative Workflows were used for Molecular Features extraction. Statistical analysis for data obtained were made with Mass Profiler Professional, including PCA-analysis and t-test with statistical significance set at p<0.05. Further tandem CID MS/MS experiment was performed for statistically selected features. Presented algorithm was used for structure annotation: ion adduct determination, generation of the empirical formulas list using isotopic distribution, and structure formula elucidation by looking for characteristic

### Table 1. Characteristics of feeding ration PK-120

| Quality indicators | %       | Vitamins and trace elements from premix in 1 kg of feed, additionally |  |
|--------------------|---------|---------------------------------------------------------------------|--|
| Moisture content   | 7.6     |                                                                     |  |
| Raw proteins       | 19.67   | A                                                                  | 27.00 (1000×IU/kg) |
| Raw fat            | 4.95    | D3                                                                 | 1.50 (1000×IU/kg)  |
| Raw cellulose      | 3.51    | E                                                                  | 125.00 (mg/kg)     |
| Raw ash            | 5.93    |                                                                     |  |
| Lysine             | 1.2     | K3                                                                 | 5.00               |
| Methionine + cysteine | 0.7   | B1                                                                | 30.00              |
| Tryptophan         | 0.2     | B2                                                                 | 20.00              |
| Ca                 | 1.00    | B3                                                                 | 30.00              |
| P                  | 0.74    | B4                                                                 | 1000.00            |
| Na                 | 0.2     | B5                                                                 | 80.00              |
| B6                 |         |                                                                     | 15.00              |
| Bc (folic acid)    |         |                                                                     | 4.00               |
| B12                |         |                                                                     | 0.050              |
| C                  |         |                                                                     | 70.00              |
| H (biotin)         |         |                                                                     | 0.040              |
| Microelements      |         |                                                                     |  |
| Mg                 |         |                                                                     | 200.00             |
| Fe                 |         |                                                                     | 100.00             |
| Mn                 |         |                                                                     | 57.00              |
| Zn                 |         |                                                                     | 53.50              |
| Cu                 |         |                                                                     | 9.00               |
| Co                 |         |                                                                     | 1.35               |
| I                  |         |                                                                     | 1.00               |
| Se                 |         |                                                                     | 0.07               |
fragmentation patterns. Empirical formulas were generated in Agilent MassHunter Qualitative Analysis Navigator. Compound class and structure formula were defined by two steps: experimental fragment spectra interpretation and in silico spectra generation, using MS-FINDER and MetFrag software\(^\text{17-19}\).

**RESULTS**

**Blood pressure**

For the ‘Control’ group the pressure was: systolic 140.79 ± 7.41, diastolic 96.34 ± 5.80 Torr. For the group ‘Lead’: systolic 134.53 ± 7.01, diastolic 93.42 ± 6.90 Torr.

**Metabolomic analysis**

Using PCA-analysis followed by t-test were extracted 38 features, presented in Table 3 (annotated features are ‘+’-marked). PCA 3D-plot is presented in Figure 1, t-test and FolgChange filtering results are presented as a Volcano-plot.

**Table 2. Results of biochemical and hematological analysis**

| Parameter                                               | Control Mean ± SD   | Lead Mean ± SD    |
|---------------------------------------------------------|---------------------|-------------------|
| Hemoglobin, g/L                                         | 148.60 ± 2.44       | 107.20 ± 3.38 *   |
| Hematocrit, %                                           | 16.73 ± 0.53        | 12.81 ± 0.21 *    |
| Peripheral blood reticulocytes, %                       | 21.75 ± 2.25        | 68.89 ± 4.90 *    |
| Erythrocytes, 10\(^12\)/mL                             | 7.17 ± 0.18         | 7.34 ± 0.17       |
| Average erythrocyte volume, μm\(^3\)                    | 46.91 ± 0.84        | 35.24 ± 0.72 *    |
| Average hemoglobin content in 1 erythrocyte, \(10^{-12}\) g | 20.78 ± 0.29        | 14.69 ± 0.29 *    |
| Average hemoglobin concentration in erythrocyte, g/L    | 436.20 ± 6.80       | 419.00 ± 12.95    |
| Erythrocyte distribution width, %                       | 14.76 ± 0.21        | 27.43 ± 0.32 *    |
| Platelets, 10\(^6\)/mL                                  | 787.09 ± 33.06      | 1454.18 ± 80.25 * |
| Platelets average volume, μm\(^3\)                      | 5.510 ± 0.091       | 9.44 ± 0.40 *     |
| Thrombocrit, %                                          | 0.2210 ± 0.0082     | 0.692 ± 0.056 *   |
| Width of platelets distribution, %                      | 12.66 ± 0.40        | 24.26 ± 1.07 *    |
| Leukocytes, 10\(^6\)/mL                                 | 11.71 ± 1.12        | 21.53 ± 1.90 *    |
| Basophiles, 10\(^6\)/mL                                 | 0.00 ± 0.00         | 0.00 ± 0.00       |
| Basophiles, %                                           | 0.00 ± 0.00         | 0.00 ± 0.00       |
| Eosinophilia, 10\(^6\)/mL                               | 0.38 ± 0.11         | 0.333 ± 0.063     |
| Eosinophilia, %                                         | 3.00 ± 0.65         | 2.00 ± 0.42       |
| Neutrophils stickyergic, 10\(^6\)/mL                    | 0.38 ± 0.11         | 0.400 ± 0.087     |
| Neutrophils stickyergic, %                              | 0.38 ± 0.11         | 0.50 ± 0.13       |
| Segmented neutrophils, 10\(^5\)/mL                      | 1.57 ± 0.16         | 4.06 ± 0.51 *     |
| Segmented neutrophils, %                                | 13.91 ± 1.27        | 18.80 ± 1.25 *    |
| Monocytes, 10\(^6\)/mL                                  | 0.656 ± 0.088       | 1.32 ± 0.19 *     |
| Monocytes, %                                            | 5.55 ± 0.39         | 5.70 ± 0.52       |
| Lymphocytes, 10\(^6\)/mL                                | 8.99 ± 0.88         | 14.55 ± 1.28 *    |
| Lymphocytes, %                                          | 76.55 ± 1.23        | 72.29 ± 0.57 *    |
| Succinate dehydrogenase, the number of formazan pellets in 50 lymphocytes | 450.20 ± 3.50       | 417.09 ± 6.40 *   |
| Overall serum protein, g/L                              | 69.39 ± 1.39        | 62.24 ± 1.54 *    |
| Albumin, g/L                                            | 44.33 ± 1.43        | 34.92 ± 0.69 *    |
| Globulins, g/L                                          | 26.58 ± 1.28        | 26.65 ± 0.96      |
| A/G index                                               | 1.698 ± 0.092       | 1.347 ± 0.046 *   |

Continued
Table 2. Continued

| Parameter                  | Control Mean ± SD | Lead Mean ± SD |
|----------------------------|-------------------|----------------|
| Alanine transaminase, E/L  | 53.54 ± 2.74      | 34.22 ± 1.03*  |
| Aspartate transaminase, E/L| 170.64 ± 10.62    | 182.90 ± 12.96|
| AST/ALT ratio              | 3.41 ± 0.27       | 5.06 ± 0.30*   |
| Glucose, mmol/L            | 5.69 ± 0.17       | 4.47 ± 0.22*   |
| Lactate, mmol/L            | 7.55 ± 0.51       | 5.60 ± 0.84**  |
| SH-groups, mmol/l          | 5.53 ± 1.89       | 4.92 ± 1.35    |
| Gamma-glutamyltransferase, eq/L | 0.50 ± 0.18 | 1.60 ± 0.28*   |
| Alkaline phosphatase, E/L  | 148.21 ± 22.76    | 125.21 ± 16.30 |
| Lactate dehydrogenase, E/L | 2450.00 ± 146.86  | 2387.27 ± 210.77|
| Amylase, E/L               | 3975.13 ± 298.38  | 2174.70 ± 138.86* |
| Catalase, mcmol/L          | 0.381 ± 0.086     | 0.381 ± 0.086  |
| Glutathione, mcmol/L       | 14.40 ± 2.07      | 12.21 ± 1.51   |
| Ceruloplasmin, mg/%        | 91.14 ± 3.37      | 113.05 ± 3.44* |
| Malondialdehyde, mcmol/L   | 5.78 ± 0.22       | 6.47 ± 0.62    |
| Serum uric acid, mcmol/L   | 83.88 ± 3.05      | 123.78 ± 5.93* |
| Bilirubin, mcmol/L         | 1.400 ± 0.088     | 1.28 ± 0.14    |
| Cholesterol, mmol/L        | 1.68 ± 0.12       | 1.54 ± 0.11    |
| High-density lipoprotein, mmol/L | 0.987 ± 0.074 | 0.745 ± 0.061* |
| Low-density lipoprotein, mmol/L | 0.261 ± 0.035 | 0.315 ± 0.032 |
| Triglycerides, mmol/L      | 1.41 ± 0.20       | 1.50 ± 0.15    |
| Calcium in serum, mmol/L   | 2.407 ± 0.042     | 2.353 ± 0.029* |
| C-reactive protein, mg/L   | 0.00 ± 0.00       | 0.01 ± 0.01    |
| Creatine kinase, E/L       | 1217.67 ± 313.73  | 953.90 ± 206.74 |
| Creatine kinase MB, E/L    | 1337.13 ± 123.30  | 1358.82 ± 105.66|
| Osteocalcin, ng/mL         | 599.12 ± 39.92    | 816.89 ± 35.96* |
| Thyroid-stimulating hormone, pg/mL | 11502.31 ± 396.57 | 12607.65 ± 349.86** |
| Vascular endothelial growth factor, IU/mL | 5.67 ± 0.40 | 5.13 ± 0.31 |
| Cortisol, nmol/L           | 73.77 ± 8.30      | 66.72 ± 10.49  |
| Angiotensin-converting enzyme, E/L | 143.00 ± 14.74 | 236.36 ± 21.95* |
| δ-Aminolevulinic acid in blood, mcg/mL | 0.85 ± 0.31 | 20.59 ± 4.77* |

*Statistically significant difference by Mann–Whitney U test and Student’s t-test. **Statistically significant difference only by Mann–Whitney U test.

Table 3. List of extracted features

| N  | m/z      | RT  | p       | Log2 (FC) | Expression in comparison to ‘Control’ |
|----|----------|-----|---------|-----------|--------------------------------------|
| 1  | 201.1649 | 16.14| <0.0001 | 18.76     | ↑                                   |
| 2  | 201.1649 | 12.47| <0.0001 | 18.12     | ↑                                   |
| 3  | 247.1704 | 16.12| <0.0001 | 17.85     | ↑                                   |
| 4  | 276.1947 | 12.51| <0.0001 | 18.42     | ↓                                   |
| N  | m/z      | RT  | p       | Log₂(FC) | Expression in comparison to 'Control' |
|----|----------|-----|---------|----------|---------------------------------------|
| +5 | 295.2278 | 9.79| <0.0001 | 18.43    | ↑                                     |
| +6 | 314.2334 | 10.05| <0.0001 | 19.73    | ↓                                     |
| +7 | 321.2436 | 16.15| <0.0001 | 18.17    | ↑                                     |
| 8  | 369.2042 | 9.75 | <0.0001 | 18.52    | ↑                                     |
| 9  | 370.8036 | 22.37| <0.0001 | 17.71    | ↓                                     |
| 10 | 375.3386 | 12.03| <0.0001 | 16.56    | ↓                                     |
| 11 | 395.2793 | 16.78| <0.0001 | 21.39    | ↑                                     |
| 12 | 398.1956 | 16.49| 0.041126| 1.00     | ↓                                     |
| 13 | 399.2166 | 12.18| <0.0001 | 18.81    | ↑                                     |
| +14| 414.3224 | 15.88| <0.0001 | 19.75    | ↑                                     |
| +15| 416.3389 | 15.22| 0.002421| 2.23     | ↑                                     |
| 16 | 438.3232 | 15.27| <0.0001 | 18.84    | ↑                                     |
| 17 | 440.3378 | 16.63| <0.0001 | 20.42    | ↑                                     |
| +18| 440.3389 | 14.64| <0.0001 | 19.53    | ↑                                     |
| +19| 442.3540 | 15.96| 0.001056| 2.82     | ↑                                     |
| 20 | 456.3342 | 11.05| <0.0001 | 19.01    | ↑                                     |
| 21 | 480.2747 | 15.69| <0.0001 | 18.92    | ↑                                     |
| 22 | 498.2855 | 15.71| 0.013552| 2.66     | ↑                                     |
| 23 | 520.2663 | 15.70| <0.0001 | 20.45    | ↑                                     |
| 24 | 520.3091 | 17.19| <0.0001 | 17.85    | ↑                                     |
| +25| 570.2844 | 12.97| <0.0001 | 18.39    | ↑                                     |
| 26 | 623.0185 | 9.26 | <0.0001 | 18.34    | ↓                                     |
| 27 | 632.0149 | 9.26 | <0.0001 | 17.76    | ↓                                     |
| 28 | 637.3464 | 9.26 | <0.0001 | 18.04    | ↓                                     |
| 29 | 662.334  | 4.66 | <0.0001 | 18.62    | ↑                                     |
| 30 | 709.7954 | 5.26 | <0.0001 | 18.00    | ↑                                     |
| 31 | 885.3552 | 14.96| <0.0001 | 16.50    | ↓                                     |
| 32 | 933.0209 | 9.26 | <0.0001 | 19.23    | ↓                                     |
| 33 | 947.5742 | 15.92| <0.0001 | 17.68    | ↓                                     |
| 34 | 947.5745 | 16.27| <0.0001 | 17.77    | ↓                                     |
| 35 | 969.5202 | 11.81| <0.0001 | 17.45    | ↑                                     |
| 36 | 1111.671 | 15.53| <0.0001 | 21.66    | ↓                                     |
| 37 | 1145.479 | 14.95| <0.0001 | 16.90    | ↓                                     |
in Figure 2. It was possible to annotate structures for eight metabolites given in Table 4.

**DISCUSSION**

**Blood lead levels**

Blood concentrations of lead were not measured in this study, but there are results of a previous experiment with the same conditions and lead dosing for lead-exposed ‘Group 4’ and ‘Control’ groups: 12036.36 ± 1670.55 mcg/L and 6.73 ± 1.97 mcg/L, correspondingly. Elevated number of platelets and the thrombocrit observed correspond to lead poisoning. Other signs of lead intoxication were observed: a decrease in total serum protein content; and particularly, albumins associated with liver disturbances. Changes in such significant liver parameters as ALT and AST vary according to the exposure route and dose – in our case ALT increased while AST remained unchanged. Lead-associated kidney disturbance is also well-known – in our case it was manifested as an elevated level of uric acid in serum.

**Metabolomic study**

The aim of this study – using an untargeted metabolomic approach, was to define substances present in the blood, which have a changed concentration under lead toxic exposure. Statistical analysis of obtaining raw data allowed us to extract 37 features, 8 of which were annotated. The term ‘annotated’ is used in the context of the Metabolomic Standards Initiative set by the Chemical Analysis Working Group, and means ‘Putatively annotated with m/z and MS/MS matching’ – 2nd level of confidence. This fact may be considered as a drawback of this study, which could be fixed by measuring standards in the future. Nevertheless, in this case, we tried to make the most detailed analysis of fragmentation spectra for each substance, to compensate for

---

**Table 4. List of annotated metabolites**

| Annotated substance | Empirical formula | m/z  |
|---------------------|-------------------|------|
| 10,13-epoxy-10,12-octadecadienic acid | C_{48}H_{80}O_{3} | 295.2278 |
| 3-Oxoctadecanoylcarnitine | C_{25}H_{47}NO_{5} | 442.3540 |
| 15-Hydroxy-5,8,11,13-eicosatetraenoic acid | C_{26}H_{32}O_{3} | 321.2436 |
| Lyso-1-docosahexaenoyl-glycero-3-phosphoserine | C_{28}H_{44}NO_{9}P | 570.2844 |
| Hydroxylinoleoilecamitine | C_{25}H_{45}NO_{5} | 440.3389 |
| 5/6-Hydroxyhexadecanoylcarnitine | C_{23}H_{45}NO_{5} | 416.3389 |
| 3-Oxohexadecanoylcarnitine | C_{23}H_{43}NO_{5} | 414.3224 |
| 4-Decenoylcarnitine | C_{17}H_{31}NO_{4} | 314.2334 |

---

**Figure 2. PCA 3D-plot**

X-Axis: Component 1 (27.61%), Y-Axis: Component 2 (26.89%), Z-Axis: Component 4 (10.37%).  ● ‘Control’ group.  ● ‘Lead’ group.

**Figure 3. T-test and FoldChange filtering results**

- ■ Passed both cut-offs and up-regulating.
- ■ Passed both cut-offs and down-regulating.
- ■ Failed to pass FoldChange cut-off.
- ■ Failed to pass both cut-offs.
this disadvantage. Twenty-nine m/z values were excluded from further consideration, so there was no possibility to establish fragmentation patterns, due to poor fragmentation spectra.

Analysis of mass spectra 10,13-epoxy-10,12-octadecadienic acid (EpODE) showed the presence of alkyl-series with general formula C\textsubscript{h}\textsubscript{2+1} with chain length 5, corresponding to unsubstituted pentyl radical (Supplementary file Figure 4). Intensive peak of [M-H+O+H]\textsuperscript{+} points to easy water elimination in case of carboxylic acid to acyl-cation formation with empirical formula C\textsubscript{18}H\textsubscript{27}O\textsubscript{2}. There is no more water loss from this cation, so a second oxygen atom belongs to a keto- or an ether-group. Next, cation 227.2128 produce a series of fragments 55.0198 – 141.1281, corresponding to the presence of unsubstituted 8-member alkyl chain in a molecule. The rest of the molecule has formula C\textsubscript{20}H\textsubscript{29}O\textsubscript{2}, which fits to double-substituted furan moiety. For EpODE, a derivative of conjugated 9,11-linoleic acid (CLA), there is no mention in previous studies in the context of lead intoxication and oxidative stress. CLA acid naturally occurs in rumens, as a conversion result of α-linoleic acid by microbial enzymes\textsuperscript{26,27}. Accordingly, CLA gets into the rat lipid pool from dietary source and may be included to membrane phospholipids to sn-1 and sn-2 positions of glycerol\textsuperscript{28,29}. EpODE – is a structural analog of the so-named furanic fatty acid (FFA) from plants and seafood, but with significant difference – the lack of a methyl group at β-carbon atom at the furan ring (Supplementary file Figure 5).

The substances discussed have antioxidative activity, but EpODE, as a unsubstituted furan derivative, possesses it at less extent\textsuperscript{30,31}. For the formation of EpODE from CLA and its elevated expression, we proposed the following hypothesis. Initially, CLA is ingested with the food source to the rat organism and incorporated into the phospholipids of blood cell membranes or remains in the blood flow. Next step – oxidation – may occur spontaneously in the presence of singlet oxygen, the reactive form of oxygen\textsuperscript{32}. This fact associated with oxidative stress, a characteristic of lead intoxication, was manifested in our study by slightly increased MDA levels. As erythrocytes bind the dominant part of lead in the blood\textsuperscript{33,34}, it could be proposed that erythrocytes cell membrane is the source of EpODE. Considering that furanic fatty acid enters mammals with plant food and seafood, where it is observed first\textsuperscript{35-38}, this substance has significant antioxidative activity\textsuperscript{39,40}. The function of this substance in mammals is thus protection from oxidative stress\textsuperscript{41}. Thus, elevated concentration of this substance in the group ‘Lead’ is a manifestation of lead-induced oxidative stress proceeding\textsuperscript{42-44}.

In the mass spectra of all annotated long-chain acylcarnitines (3-oxooctadecanoylcarnitine (3-0ODC), hydroxylinoleoilecarnitine (HLC), 5/6-hydroxyhexadecanoylcarnitine (5/6-HHDC), 3-oxohexadecanoylcarnitine (3-OHDC)) were observed neutral losses from bond cleavages in position 1 (59.0735 – C\textsubscript{2}H\textsubscript{N}), 1+3 (102.0230 – C\textsubscript{H}_{10}O\textsubscript{2}), and 3 (161.1009 – C\textsubscript{H}_{14}NO\textsubscript{2}). Also, there are characteristic fragments from these cleavages: 1 (60.0807 – C\textsubscript{18}H\textsubscript{17}N), 1+2 (85.0287 – C\textsubscript{18}H\textsubscript{20}O\textsubscript{2}), and 2 (144.1038 – C\textsubscript{18}H\textsubscript{23}NO\textsubscript{2}) (Supplementary file Figure 6)\textsuperscript{45}. Empirical formulae of 3-OODC and 3-OHDC show that these substances are homologues. The position of the keto-group was estimated by the presence of neutral loss C\textsubscript{18}H\textsubscript{15}O\textsubscript{2} (cleavage 4) from ketoacylum ion (281.2522 for 3-OODC and 253.2154 for 3-OHDC), with formation of acyl-cation-shorter on two carbon atoms than the parent ion (239.2395 and 211.2060, respectfully). Taking it to account, it could be proposed that the keto-group belongs to third carbon atom. Acyl-cation with eliminated water from fragmentation of HLC was C\textsubscript{18}H\textsubscript{25}O – it shows the presence of 4 double bonds: one belongs to the keto-group, the second corresponds to water cleavage, and other two to the initial alkyl radical. Naturally formed fatty acid with two double bonds is a linoleic acid, so the positions of these double bonds could be at 9 and 12 carbon atoms. It was not possible to estimate from mass spectra a position of the third double bond, corresponding to the position of the hydroxy group. Mass spectra of 5/6-HHDC have alkyl series from C\textsubscript{18}H\textsubscript{25}O to C\textsubscript{18}H\textsubscript{28}O, which fits to double-substituted furan moiety. For CLA, there is no mention in previous studies in the context of the β-oxidation cycle and oxidative stress. CLA acid gets into the rat lipid pool from dietary source and may be included to membrane phospholipids to sn-1 and sn-2 positions of glycerol\textsuperscript{28,29}. EpODE is a structural analog of the so-named furanic fatty acid (FFA) from plants and seafood, but with significant difference – the lack of a methyl group at β-carbon atom at the furan ring (Supplementary file Figure 5).
(positions 1, 2 and their combinations). Retro-ene rearrangement of acyl-cation \( \text{C}_{10}\text{H}_{17}\text{O} \) (153.1282) leads to the formation of fragment 97.0644 (\( \text{C}_{7}\text{H}_{8}\text{O} \), cleavages at 3 and 4 positions) – this fact corresponds to the double bond position between the fourth and fifth carbon atoms (Supplementary file Figure 7). Middle-chain fatty acids are able to enter mitochondria with and without passing the carnitine transport system\(^{55}\). Due to \( \beta \)-oxidation cycle disturbances, discussed above, there is a deficit of carnitine in mitochondria, so a non-carnitine way for middle chain acid was more preferable – a lack of free carnitine was also observed in the other lead intoxication study\(^{69}\). This fact explains the reduced concentration of 4-decenoylcarnitine in lead-exposed group in comparison to the control group.

Characteristic losses and fragments of lysophosphatidylserines are observed in mass spectra of Lyso-1-docosahexaenoyl-glycero-3-phosphoserine (LysoPS(22:6)) (1 - 87.0309, 1+2 - 97.9763, 2+3 - 74.0380)\(^{56}\) (Supplementary file Figure 8). The hydrocarbon radical of acylation-cation has six double bonds – these positions were estimated by RDB indices of alkyl and acyl fragmentation series. It is known that lead exposure increases apoptotic processes in mammals\(^{65}\). Enrichment of outer cell membrane surface with serine-containing phospholipids is one of the apoptosis stages\(^{68}\). These substances are used by macrophages for localizing and absorbing apoptotic cells. The following mechanism of the phenomenon is proposed. Specific phosphatidylserine-phospholipase A2 produced by platelets, hydrolyze phospholipids of apoptotic cells, with Specific phosphatidylserine-phospholipase A2 produced by platelets, hydrolyze phospholipids of apoptotic cells, with elimination of LysoPS. This substance, in turn, provides apoptotic cell engulfment by macrophages\(^{59}\). Thus, increasing of LysoPS(22:6) concentration in exposed to lead group may serve as a marker of intensification of the apoptotic processes – this fact is also confirmed by the results of previous metabolomic investigations\(^{60-62}\).

Fragmentation of 15-Hydroxy-5,8,11,13-eicosatetraenoic acid (15-HETE) begins with the elimination of two water molecules: one from carboxyl group, another from hydrocarbon radical (Supplementary file Figure 9). Leftover acyl-cation further dissociates to fragments \( \text{C}_{7}\text{H}_{8}\text{O} \) (71.0868) and \( \text{C}_{7}\text{H}_{10}\text{O} \) (55.0178) – this fact points to the five double bonds located between C5 and C15. The set of fragments from \( \text{C}_{9}\text{H}_{8}\text{O} \) (97.0656) to \( \text{C}_{10}\text{H}_{13}\text{O} \) (149.0965) points to double bond positions at C5, C8, and C11\(^{53}\). The last double bond is located at the conjugating position at C13, and hydroxy-group at C15 – a consequence of initial oxygen attachment to the double bond at C14. Increased expression of 15-HETE was observed on exposure to ambient nanoparticles, containing, in general, polyconjugated aromatic hydrocarbons and heavy metals (including lead)\(^{64}\), and at neuroinflammation process\(^{65}\). Hypoxia and oxidative stress are reasons of apoptotic processes, discussed above. It is known that oxygen deficit leads to activation of macrophage’s 15-lipoxygenase ferment\(^{66}\). This ferment catalyzes formation of 15-HETE from arachidonic acid, presenting in a cell membrane pool of macrophages\(^{67}\). This substance possesses anti-inflammatory function, due to inhibiting 5- and 12-lipoxygenase ferments, accordingly reduce the concentration of proinflammatory eicosanoids\(^{68,69}\). Hematological analysis for the ‘Lead’ group shows an increased number of leukocytes, which corresponds to inflammation, so expression of 15-HETE may be a manifestation of a compensatory mechanism, aimed to decrease inflammation. As for apoptotic process intensification, it is known, that 15-HETE possesses the antiapoptotic effect, which acts as an inhibitor of apoptogenic peptides. Elevated concentration of 15-HETE may also serve as a sign of passing antiapoptotic regulatory mechanism.

CONCLUSIONS

Changes in concentration of hydroxy- and oxo-acylcarnitine, in the context of \( \beta \)-oxidation process, may serve as a marker of disturbances in this process for the lead-exposed group, due to lead-induced oxidative stress and hypoxia. Furanic and 15-hydroxy-derivatives of polysaturated fatty acids, relevant to oxidative stress, may take part in antiapoptotic and antioxidative mechanisms, and also serve as biomarkers of these processes. Lysodocosahexaenoylphosphoserine (22:6), observed in larger quantity in the lead-exposed group, means intensification of apoptotic processes under lead exposure, which is consistent with existing literature, so this substance may serve as a biomarker in this context.

REFERENCES

1. Seleznev AA, Yarmoshenko IV, Malinovsky GP. Urban geochemical changes and pollution with potentially harmful elements in seven Russian cities. Sci Rep. 2020;10(1):1668. doi:10.1038/s41598-020-58434-4
2. Liu G, Yu Y, Hou J, et al. An ecological risk assessment of heavy metal pollution of the agricultural ecosystem near a lead-acid battery factory. Ecol Indic. 2014; 47:210-218. doi:10.1016/j.ecolind.2014.04.040
3. Snakin VV, Prisyazhnaya AA. Lead contamination of the environment in Russia. Sci Total Environ. 2000;256(2-3):95-101. doi:10.1016/s0048-9697(00)00452-6
4. Simons TJ. Cellular interactions between lead and calcium. Br Med Bull. 1986;42(4):431-434. doi:10.1093/oxfordjournals.bmb.a072162
5. Habermann E, Crowell K, Janicki P. Lead and other metals can substitute for Ca2+ in calmodulin. Arch Toxicol. 1983;54(1):61-70. doi:10.1007/BF00277816
6. Batra N, Nehru B, Bansal MP. Reproductive potential of male Portan rats exposed to various levels of lead with regard to zinc status. Br J Nutr. 2004;91(3):387-391. doi:10.1079/BJN20031066
7. Wang Q, Luo W, Zheng W, et al. Iron supplement prevents lead-induced disruption of the blood-brain barrier during rat development. Toxicol Appl Pharmacol. 2007;219(1):33-41. doi:10.1016/j.taap.2006.11.035
8. Turgut S, Polat A, Inan M, et al. Interaction between
anemia and blood levels of iron, zinc, copper, cadmium and lead in children. Indian J Pediatr. 2007;74(9):827-830. doi:10.1007/s12098-007-0147-2

9. Eguchi A, Nomiyama K, Sakurai K, et al. Alterations in urinary metabolomic profiles due to lead exposure from a lead-acid battery recycling site. Environ Pollut. 2018;242(Pt A):98-105. doi:10.1016/j.envpol.2018.06.071

10. Hammond PB. Exposure of humans to lead. Annu Rev Pharmacol Toxicol. 1977;17(1):197-214. doi:10.1146/annurev.ph.17.020177.001213

11. Cleveland LM, Minter ML, Cobb KA, Scott AA, German VF. Lead hazards for pregnant women and children: part 1: immigrants and the poor. Part 2 should most of the burden of lead exposure in this country. Part 1 of a two-part article details how exposure happens, whom it affects, and the harm it can do. Am J Nurs. 2008;108(10):40-49. doi:10.1097/01.NAJ.0000337736.76730.66

12. Flora G, Gupta D, Tiwari A. Toxicity of lead: A review with recent updates. Interdiscip Toxicol. 2012;5(2):47-58. doi:10.2478/v10102-012-0009-2

13. Kelly RS, Bayne H, Spiro A et al. Metabolomic signatures of lead exposure in the VA Normative Aging Study. Environ Res. 2020;190:110022. doi:10.1016/j.envres.2020.110022

14. Klinova SV, Minigalieva IA, Privalova LI, et al. Further verification of some postulates of the combined toxicity theory: New animal experimental data on separate and joint adverse effects of lead and cadmium. Food Chem Toxicol. 2020;136:110971. doi:10.1016/j.fct.2019.110971

15. Tietz NW. Clinical Guide to Laboratory Tests. 3rd ed. WB Saunders Company; 1995.

16. Cheng M, Wu H, Wu H, Liu X, Zhou A. Metabolic profiling of copper-laden hepatolenticular degeneration model rats and the interventional effects of Gandou decoction using UPLC-Q-TOF/MS. J Pharm Biomed Anal. 2019;164:187-195. doi:10.1016/j.jpba.2018.10.041

17. Tsugawa H, Kind T, Nakabayashi R, et al. Hydrogen Rearrangement Rules: Computational MS/MS Fragmentation and Structure Elucidation Using MS-FINDER Software. Anal Chem. 2016;88(16):7946-7958. doi:10.1021/acs.analchem.6b00770

18. Lai Z, Tsugawa H, Wohlgemuth G, et al. Identifying metabolites by integrating metabolome databases with mass spectrometry cheminformatics. Nat Methods. 2018;15(1):53-56. doi:10.1038/nmeth.4512

19. Ruttkies C, Schymanski EL, Wolf S, Hollender J, Neumann S. MetFrag relaunched: incorporating strategies beyond in silico fragmentation. J Cheminform. 2016;8:3. doi:10.1186/s13321-016-0115-9

20. Protsenko YL, Katsnelson BA, Klinova SV, et al. Effects of subchronic lead intoxication of rats on the myocardium contractility. Food Chem Toxicol. 2018;120:378-389. doi:10.1016/j.fct.2018.07.034

21. Al Momen A. Thrombocytosis secondary to chronic lead poisoning. Platelets. 2010;21(4):297-299. doi:10.3109/09537101003612813

22. Andjelkovic M, Buha Djordjevic A, Antonijevic E, et al. Toxic Effect of Acute Cadmium and Lead Exposure in Rat Blood, Liver, and Kidney. Int J Environ Res Public Health. 2019;16(2):274. doi:10.3390/ijerph16020274

23. Yilmaz H, Keten A, Karacaoglu E, Tutkun E, Akcan R. Analysis of the hematological and biochemical parameters related to lead intoxication. J Forensic Leg Med. 2012;19(8):452-454. doi:10.1016/j.jflm.2012.04.001

24. Wani AL, Ara A, Usmani JA. Lead toxicity: a review. Interdiscip Toxicol. 2015;8(5):55-64. doi:10.1515/intox-2015-0009

25. Godzien J, Gil de la Fuente A, Otero A, Barbaz C. Metabolite annotation and identification. In: Jaumot J, Bedia C, Tauler R, eds. Comprehensive Analytical Chemistry. Vol 82. Elsevier; 2018:415-445.

26. Palmquist DL, Lock AL, Shingfield KJ, Bauman DE. Biosynthesis of conjugated linoleic acid in ruminants and humans. Adv Food Nutr Res. 2005;50:179-217. doi:10.1016/S1043-4526(05)50006-8

27. Aydin R. Conjugated Linoleic Acid: Chemical Structure, Sources and Biological Properties. Turk J Vet Anim Sci. 2005;29:189-195. Accessed November 24, 2021. https://journals.tubitak.gov.tr/veterinary/issues/vet-05-29-2/vet-29-2-1-0308-11.pdf

28. Subbajah PV, Gould IG, Lal S, Aizebi Z. Incorporation profiles of conjugated linoleic acid isomers in cell membranes and their positional distribution in phospholipids. Biochim Biophys Acta. 2011;1811(1):17-24. doi:10.1016/j.bbalip.2010.09.004

29. Field C, Schley PD. Evidence for potential mechanisms for the effect of conjugated linoleic acid on tumor metabolism and immune function: lessons from n-3 fatty acids. Am J Clin Nutr. 2004;79(6 Suppl):1190S-1198S. doi:10.1093/ajcn/79.6.1190S

30. Vetter W, Wendlinger C. Furan fatty acids - valuable minor fatty acids in food. Lipid Technol. 2013;25(1):7-10. doi:10.1002/lite.201300247

31. Lemke RA, Peterson AC, Ziegelhoffer EC, et al. Synthesis and Dynamics of Lead Contents in Human Erythrocytes Revealed by Single-Cell Analysis. Environ Sci Technol. 2014;111(33):E3450-E3457. doi:10.1021/es503620n

32. Yurawecz MP, Gougeon M, Moossa MM, Roach JA, Ku Y. Furan fatty acids determined as oxidation products of conjugated octadecadienoic acid. Lipids. 1995;30(7):595-598. doi:10.1002/lite.201300247

33. Sharma S, Sharma V, Paliwal R. Lead toxicity, oxidative damage and health implications. A review. International Journal for Biotechnology and Molecular Biology Research. 2011;2(13):215-221. doi:10.5897/IfBMRX11.002

34. Liu N, Huang Y, Zhang H, et al. Unified Probability Distribution Sources and Biological Properties. Turk J Vet Anim Sci. 2005;29:189-195. Accessed November 24, 2021. https://journals.tubitak.gov.tr/veterinary/issues/vet-05-29-2/vet-29-2-1-0308-11.pdf

35. Lai Z, Tsugawa H, Wohlgemuth G, et al. Identifying metabolites by integrating metabolome databases with mass spectrometry cheminformatics. Nat Methods. 2018;15(1):53-56. doi:10.1038/nmeth.4512

36. Ruttkies C, Schymanski EL, Wolf S, Hollender J, Neumann S. MetFrag relaunched: incorporating strategies beyond in silico fragmentation. J Cheminform. 2016;8:3. doi:10.1186/s13321-016-0115-9

37. Protsenko YL, Katsnelson BA, Klinova SV, et al. Effects of subchronic lead intoxication of rats on the myocardium contractility. Food Chem Toxicol. 2018;120:378-389. doi:10.1016/j.fct.2018.07.034

38. Al Momen A. Thrombocytosis secondary to chronic lead poisoning. Platelets. 2010;21(4):297-299. doi:10.3109/09537101003612813
Research paper

49. Mani MS, Joshi MB, Shetty RR, et al. Lead exposure induces mitochondrial permeability, transport, and energy-coupling processes. J Bioenerg Biomembr. 1976;8(6):293-311. doi:10.1007/BF00765158

50. Wojtczak L. Effect of long-chain fatty acids and acyl-CoA on mitochondrial permeability, transport, and energy-coupling processes. J Bioenerg Biomembr. 1976;8(6):293-311. doi:10.1007/BF00765158

51. Su X, Han X, Mancuso DJ, Abendschein DR, Gross RW. Accumulation of long-chain acylcarnitine and 3-hydroxy acylcarnitine molecular species in diabetic myocardium: identification of alterations in mitochondrial fatty acid processing in diabetic myocardium by shotgun lipidomics. Biochemistry. 2005;44(13):5234-5245. doi:10.1021/bi047773a

52. Violante S, Ijlst L, Te Brinke H, et al. Carnitine palmitoyltransferase 2 and carnitine/acylcarnitine translocase are involved in the mitochondrial synthesis and export of acylcarnitines. FASEB J. 2013;27(5):2039-2044. doi:10.1096/fj.12-216689

53. Ferreira de Mattos G, Costa C, Savio F, Alonso M, Nicolson GL. Lead poisoning: acute exposure of the heart to lead ions promotes changes in cardiac function and Cav1.2 ion channels. Biophys Rev. 2017;9(5):807-825. doi:10.1007/s12551-017-0303-5

54. Chen Z, Hsu X, Chen G, Luo X, Xu X. Lead (Pb) exposure and heart failure risk. Environ Sci Pollut Res Int. 2021;28(23):28833-28847. doi:10.1007/s11356-021-13725-9

55. Papamandiaris AA, MacDougall DE, Jones PJ. Medium chain fatty acid metabolism and energy expenditure: obesity treatment implications. Life Sci. 1998;62(14):1203-1215. doi:10.1016/s0024-3205(97)01143-0

56. Taguchi R, Houjou T, Nakashima H, et al. Focused lipidomics by tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2005;823(1):26-36. doi:10.1016/j.jchromb.2005.06.005

57. Ahmed MB, Ahmed MI, Mekh RB, Abdah M. Neurotoxic effect of lead on rats: Relationship to Apoptosis. Int J Health Sci (Qassim). 2013;7(2):192-199. doi:10.12816/0006042

58. Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine exposure on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods. 1995;184(1):39-51. doi:10.1016/0022-1759(95)00072-i

59. Kagan VE, Glies B, Tyurina YY, et al. A role for oxidative stress in apoptosis: oxidation and externalization of phosphatidylserine is required for macrophage clearance of cells undergoing Fas-mediated apoptosis. J Immunol. 2002;169(1):487-499. doi:10.4049/jimmunol.169.1.487

60. Metwaly S, Cote A, Donnelly SJ, Banoel MM, Mourad AI, Winston BW. Evolution of ARDS biomarkers: Will metabolomics be the answer? Am J Physiol Lung Cell Mol Physiol. 2018;315(4):L526-L534. doi:10.1152/ajplung.00072.2018

61. Murley AG, Jones PS, Coyle Gilchrist I, et al. Metabolomics changes associated with frontotemporal lobar degeneration syndromes. J Neurol. 2020;267(8):2228-2238. doi:10.1007/s00245-020-10171-2

62. Segawa K, Nagata S. An Apoptotic 'Eat Me' Signal: Phosphatidylserine Exposure. Trends Cell Biol. 2015;25(11):639-650. doi:10.1016/j.tcb.2015.08.003

63. Murphy RC, Fiedler J, Hevkjo J. Analysis of nonvolatile lipids by mass spectrometry. Chem Rev. 2001;101(2):479-526. doi:10.1021/cr9900883

64. Feng J, Cavallaro S, Hsiai T, Li R. Impact of air pollution on the concentration of 3-carboxy-4-tricornutum. Biochim Biophys Acta. 1993;1166(2-3):171-176. doi:10.1016/0005-2760(93)90093-o
65. Lin S, Liu H, Kanawati B, et al. Hippocampal metabolomics using ultrahigh-resolution mass spectrometry reveals neuroinflammation from Alzheimer's disease in CRND8 mice. Anal Bioanal Chem. 2013;405(15):5105-5117. doi:10.1007/s00216-013-6825-1

66. Profita M, Sala A, Riccobono L, et al. 15-Lipoxygenase expression and 15(S)-hydroxyeicosatetraenoic acid release and reincorporation in induced sputum of asthmatic subjects. J Allergy Clin Immunol. 2000;105(4):711-716. doi:10.1067/mai.2000.105122

67. Metryka E, Chibowska K, Gutowska I, et al. Lead (Pb) Exposure Enhances Expression of Factors Associated with Inflammation. Int J Mol Sci. 2018;19(6):1813. doi:10.3390/ijms19061813

68. Vanderhoek JY, Bryant RW, Bailey JM. Inhibition of leukotriene biosynthesis by the leukocyte product 15-hydroxy-5,8,11,13-eicosatetraenoic acid. J Biol Chem. 1980;255(21):10064-10066. doi:10.1016/S0021-9258(19)70428-1

69. Vanderhoek JY, Bryant RW, Bailey JM. 15-hydroxy-5,8,11,13-eicosatetraenoic acid: A potent and selective inhibitor of platelet lipoxygenase. J Biol Chem. 1980;255(13):5996-5998 doi:10.1016/S0021-9258(18)43684-8

CONFLICTS OF INTEREST
The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none was reported.

FUNDING
This work was supported as part of the sectorial research program of Rospotrebnadzor 'Hygienic scientific substantiation of health risks minimization for Russia population' for 2016–2020.

ETHICAL APPROVAL AND INFORMED CONSENT
The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Local Ethics Committee of the Yekaterinburg Medical Research Center for Prophylaxis and Health Protection in Industrial Workers (Protocol No 8; 18 November 2018).

DATA AVAILABILITY
The data supporting this research are available from the authors on reasonable request.

AUTHORS' CONTRIBUTIONS
AIC: concept and design of the study, collection and processing of material, statistical processing, writing of text. MPS: concept and design of the study, editing, approval of the final version of the article, responsibility for the integrity of all parts of the article. IAM: concept and design of the study. SVK: concept and design of the study, collection and processing of material, statistical processing. JVR: collection and processing of material, statistical processing.

PROVENANCE AND PEER REVIEW
Not commissioned; externally peer reviewed.